12/12
09:12 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its "buy" rating reaffirmed by analysts at B. Riley.
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) had its "buy" rating reaffirmed by analysts at B. Riley.
12/12
07:12 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its "outperform" rating reaffirmed by analysts at Wedbush.
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) had its "outperform" rating reaffirmed by analysts at Wedbush.
12/10
07:39 am
wve
Wave Life Sciences: 200% Rally On 1% Weight Loss Feels Bloated [Seeking Alpha]
Low
Report
Wave Life Sciences: 200% Rally On 1% Weight Loss Feels Bloated [Seeking Alpha]
12/10
01:56 am
wve
Wave Life Science prices upsized $350M stock ofeering [Seeking Alpha]
Medium
Report
Wave Life Science prices upsized $350M stock ofeering [Seeking Alpha]
12/9
11:18 pm
wve
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants [Yahoo! Finance]
Medium
Report
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants [Yahoo! Finance]
12/9
09:50 pm
wve
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Medium
Report
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
12/9
08:53 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its price target raised by analysts at Cantor Fitzgerald from $12.00 to $34.00. They now have an "overweight" rating on the stock.
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) had its price target raised by analysts at Cantor Fitzgerald from $12.00 to $34.00. They now have an "overweight" rating on the stock.
12/9
08:44 am
wve
WAVE Life Sciences (NASDAQ:WVE) was given a new $30.00 price target on by analysts at UBS Group AG.
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) was given a new $30.00 price target on by analysts at UBS Group AG.
12/9
07:21 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
12/9
07:21 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
12/8
07:00 pm
wve
WAVE Life Sciences (NASDAQ:WVE) was given a new $28.00 price target on by analysts at Morgan Stanley.
High
Report
WAVE Life Sciences (NASDAQ:WVE) was given a new $28.00 price target on by analysts at Morgan Stanley.
12/8
06:07 pm
wve
WAVE Life Sciences (NASDAQ:WVE) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
12/8
06:07 pm
wve
WAVE Life Sciences (NASDAQ:WVE) was upgraded by analysts at Royal Bank Of Canada from a "sector perform" rating to an "outperform" rating.
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) was upgraded by analysts at Royal Bank Of Canada from a "sector perform" rating to an "outperform" rating.
12/8
05:01 pm
wve
WAVE Life Sciences (NASDAQ:WVE) was given a new $40.00 price target on by analysts at Canaccord Genuity Group Inc..
High
Report
WAVE Life Sciences (NASDAQ:WVE) was given a new $40.00 price target on by analysts at Canaccord Genuity Group Inc..
12/8
04:02 pm
wve
WAVE Life Sciences (NASDAQ:WVE) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
High
Report
WAVE Life Sciences (NASDAQ:WVE) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
12/8
04:01 pm
wve
Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
High
Report
Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
12/8
07:30 am
wve
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
High
Report
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
12/7
04:00 pm
wve
Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025
High
Report
Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025
12/5
04:18 pm
wve
Wave Life Sciences: Being Realistic, There Is Still So Much To Prove [Seeking Alpha]
High
Report
Wave Life Sciences: Being Realistic, There Is Still So Much To Prove [Seeking Alpha]
11/17
10:09 am
wve
Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead [Seeking Alpha]
Low
Report
Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead [Seeking Alpha]
11/16
10:26 pm
wve
Jefferies Maintains “Buy” Rating on Wave Life Sciences (WVE) Amid Its Improving Competitive Positioning [Yahoo! Finance]
Neutral
Report
Jefferies Maintains “Buy” Rating on Wave Life Sciences (WVE) Amid Its Improving Competitive Positioning [Yahoo! Finance]
11/13
06:30 am
wve
WAVE Life Sciences Ltd (WVE) Q3 2025 Earnings Call Highlights: Promising Clinical Advances and ... [Yahoo! Finance]
Medium
Report
WAVE Life Sciences Ltd (WVE) Q3 2025 Earnings Call Highlights: Promising Clinical Advances and ... [Yahoo! Finance]
11/11
10:10 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its price target raised by analysts at Wedbush from $18.00 to $20.00. They now have an "outperform" rating on the stock.
Low
Report
WAVE Life Sciences (NASDAQ:WVE) had its price target raised by analysts at Wedbush from $18.00 to $20.00. They now have an "outperform" rating on the stock.
11/11
09:44 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its price target lowered by analysts at Wells Fargo & Company from $18.00 to $16.00. They now have an "overweight" rating on the stock.
Low
Report
WAVE Life Sciences (NASDAQ:WVE) had its price target lowered by analysts at Wells Fargo & Company from $18.00 to $16.00. They now have an "overweight" rating on the stock.
11/10
07:59 am
wve
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]